The FDA recently approved a new subcutaneous specialty therapy, Uzedy (risperidone) from TEVA and MedinCell, an atypical antipsychotic indicated for the treatment of schizophrenia in
We’ve reported several times on the disparity of specialty drug pricing based on where the drugs are administered. None of our readers would be surprised that
The FDA recently approved a new gene therapy, Omisirge (omidubicel-onlv) from Gamida Cell Ltd., for use in adult and pediatric patients (12 years and older)
What do ‘ya get from a DNA modified pig? …………. wait for it……………….. ………….wait for it……………….. …………………..CRISPR BACON! 😊 DNA modification is about to trigger a
This week the FDA approved a new therapy, Qalsody (tofersen) from Biogen MA, Inc., for the treatment of amyotrophic lateral sclerosis (ALS) in adults who
Most would agree that the US has been a litigious-heavy country for decades. As we know, healthcare is one of the biggest targets for lawsuits of
The article below is one that a specialty pharmacy’s legal counsel might find most interesting. In short, the US District Court ruling below said that Humana
The FDA recently approved a therapy previously approved in 2021….. but with a very different indication and a new NDC. The approval was granted for Syfovre
Ever get a letter from more than 400 people? Not 400 letters…. 1 letter with four hundred+ signatories! Over the last week more than 400 of
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
